Sonic Incytes Announces Multi-Year Partnership with Madrigal Pharmaceuticals to Advance Non-Invasive Liver Assessment in MASH

Sonic Incytes and Madrigal Pharmaceuticals (MDGL) announced a multi-year partnership to advance non-invasive liver assessment for MASH. Sonic Incytes' Velacur platform will be used to help clinicians assess and risk-stratify patients. The partnership aims to expand the use of non-invasive tests at the point of care, with a focus on gastroenterology, hepatology, and endocrinology settings.

Original reporting
Published Nov 19, 2026, 1:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 19, 2026, 2:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Sonic Incytes Announces Multi-Year Partnership with Madrigal Pharmaceuticals to Advance Non-Invasive Liver Assessment in MASH — source image
Decision brief

The 30-second read

$MDGLBullishLow
01

Why it matters

The partnership aims to expand use of non-invasive tests at the point of care, potentially improving earlier identification and risk stratification of patients at risk for MASH.

02

Market read

For MDGL, the news is a diagnostic workflow partnership that could support patient identification for MASH care, but it provides no financial metrics or near-term milestones.

03

What to watch

Diagnostic adoption depends on clinician uptake, payer reimbursement, and integration into existing workflows; these constraints are not addressed in the article.

Relevance 6/10Novelty 5/10Timing: today’s announcement, no scheduled follow-on dates provided

Background

MASH is described as significantly underdiagnosed, with limited community access to liver elastography contributing to delayed assessment.

Company-level read

Ticker impact

$MDGLBullishMedium confidence
Context

Madrigal (MDGL) enters a multi-year partnership with Sonic Incytes to expand point-of-care non-invasive MASH liver assessment using Velacur.

Expected impact

Likely modest positive bias as investors view improved diagnostic access as incremental demand support for MASH treatment adoption.

Evidence & confidence

The article is a product-adoption partnership rather than a financial disclosure, but it directly links MDGL’s MASH focus to broader clinical use of a diagnostic tool.

Market effects

Reinforces the MASH ecosystem shift toward non-invasive, point-of-care diagnostics to address underdiagnosis.

No specific regional market impact beyond US clinical adoption framing.

Could support broader global adoption of non-invasive liver assessment approaches, but the article is US-focused.

Counterpoint

Without disclosed commercial terms, reimbursement coverage, or adoption targets, the partnership may have limited near-term revenue impact.

Key entities

  • Sonic Incytes Medical Corp.

    Developer of the Velacur point-of-care liver assessment platform (Velacur/Velacur ONE).

  • Madrigal Pharmaceuticals, Inc.

    MASH-focused biopharmaceutical company (Nasdaq: MDGL) with an approved therapy and pipeline.

  • Velacur™ / Velacur ONE

    AI-guided ultrasound elastography device for point-of-care liver stiffness and fat fraction-related measures (including VDFF).

Related articles

$MDGLMed

Madrigal reports real-world data on liver disease drug Rezdiffra

Madrigal Pharmaceuticals (MDGL) presented real-world data on its liver disease drug Rezdiffra at a liver disease conference. Studies showed 37% to 55% of patients achieved at least 25% improvement in liver stiffness after a year, with 83% to 93% improving or stabilizing. Safety findings were consistent with clinical trials. Rezdiffra is approved for treating adults with MASH.

$MDGLMedAI 8/10

Madrigal (MDGL) Q3 2026 Earnings Call Transcript

Madrigal Pharmaceuticals (MDGL) reported Q3 2026 net sales of $431M, up 50% YoY, driven by demand for Rezdiffra. The company had 55,850 active Rezdiffra patients, nearly double the previous year. Madrigal expects the U.S. F2/F3 MASH market to grow 30% by year-end, with Rezdiffra penetrating about 1% of the total opportunity.